Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
Bio-Techne (NASDAQ: TECH) declared a quarterly dividend of $0.08 per share for the quarter ended March 31, 2024. The dividend will be payable on May 24, 2024, to common shareholders of record on May 13, 2024. The company is a global life sciences provider of tools and bioactive reagents for research and clinical diagnostics, generating $1.1 billion in net sales in fiscal 2023.
Bio-Techne appointed Dr. Judith Klimovsky as an independent director on the Board of Directors, bringing valuable experience from the biotechnology industry. Dr. Klimovsky's background in antibody therapeutics and global clinical development positions her well to contribute to Bio-Techne's expansion efforts. The addition of Dr. Klimovsky enhances the board's expertise and diversity, with a focus on Latin America and global biopharma.